UB Paderborn / Katalog / Suche / in CDI

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

The lancet oncology, 2017-02, Vol.18 (2), p.230-240

2017

Volltextzugriff (PDF)

Rapid enhancement of two-step wiring plasticity by estrogen and NMDA receptor activity

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (38), p.14650-14655

2008

Volltextzugriff (PDF)

Antinociceptive effects of MSVIII-19, a functional antagonist of the GluK1 kainate receptor

Pain (Amsterdam), 2011-05, Vol.152 (5), p.1052-1060

2011

Volltextzugriff (PDF)

Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurones

The Journal of physiology, 2005-05, Vol.564 (3), p.907-921

2005

Volltextzugriff (PDF)

Small-Molecule Intramimics of Formin Autoinhibition: A New Strategy to Target the Cytoskeletal Remodeling Machinery in Cancer Cells

Cancer research (Chicago, Ill.), 2013-11, Vol.73 (22), p.6793-6803

2013

Volltextzugriff (PDF)

Isolation, Amino Acid Sequence and Biological Activities of Novel Long-Chain Polyamine-Associated Peptide Toxins from the Sponge Axinyssa aculeata

Chembiochem : a European journal of chemical biology, 2011-09, Vol.12 (14), p.2191-2200

2011

Volltextzugriff (PDF)

PB2088: ABBV‐383 IN COMBINATION WITH ANTI‐CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION

HemaSphere, 2023-08, Vol.7 (S3), p.e60985f9-n/a

2023

Volltextzugriff (PDF)

Full Domain Closure of the Ligand-binding Core of the Ionotropic Glutamate Receptor iGluR5 Induced by the High Affinity Agonist Dysiherbaine and the Functional Antagonist 8,9-Dideoxyneodysiherbaine

The Journal of biological chemistry, 2009-05, Vol.284 (21), p.14219-14229

2009

Volltextzugriff (PDF)

Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine

Neuropharmacology, 2010-03, Vol.58 (3), p.640-649

2010

Volltextzugriff (PDF)

Total Synthesis and Biological Evaluation of Neodysiherbaine A and Analogues

Journal of organic chemistry, 2006-07, Vol.71 (14), p.5208-5220

2006

Volltextzugriff (PDF)

Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors

The Journal of pharmacology and experimental therapeutics, 2008-02, Vol.324 (2), p.484

2008

Volltextzugriff (PDF)

Critical Roles for the M3 S2 Transduction Linker Domain in Kainate Receptor Assembly and Postassembly Trafficking

The Journal of neuroscience, 2007-09, Vol.27 (39), p.10423-10433

2007

Volltextzugriff (PDF)

Cover Picture: Isolation, Amino Acid Sequence and Biological Activities of Novel Long-Chain Polyamine-Associated Peptide Toxins from the Sponge Axinyssa aculeata (ChemBioChem 14/2011)

Chembiochem : a European journal of chemical biology, 2011-09, Vol.12 (14), p.2101-2101

2011

Volltextzugriff (PDF)

Abstract 2130: Small molecule activation of diaphanous-related formins as a novel anti-cancer strategy

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2130-2130

2013

Volltextzugriff (PDF)

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S188-S189

2023

Volltextzugriff (PDF)

Abstract 2539: Reactivating tumor suppression with small-molecule deregulators of the Rho-regulated diaphanous-related formin autoinhibitory mechanism

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2539-2539

2010

Volltextzugriff (PDF)

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Blood, 2016-12, Vol.128 (22), p.3230-3230

2016

Volltextzugriff (PDF)

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Blood, 2022-11, Vol.140 (Supplement 1), p.10122-10123

2022

Volltextzugriff (PDF)

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7326-7327

2022

Volltextzugriff (PDF)

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7261-7263

2022

Volltextzugriff (PDF)

Mechanisms of membrane estrogen receptor-α-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line

American journal of physiology: endocrinology and metabolism, 2005-02, Vol.51 (2), p.E388-E397

2005

Volltextzugriff (PDF)

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies

Future oncology (London, England), 2018-09, Vol.14 (21), p.2115-2129

2018

Volltextzugriff (PDF)

Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2016-09, Vol.16, p.S50-S51

2016

Volltextzugriff (PDF)

Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2016-09, Vol.16, p.S51-S51

2016

Volltextzugriff (PDF)

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood, 2016-12, Vol.128 (22), p.2033-2033

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

Rapid enhancement of two-step wiring plasticity by estrogen and NMDA receptor activity

Antinociceptive effects of MSVIII-19, a functional antagonist of the GluK1 kainate receptor

Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurones

Small-Molecule Intramimics of Formin Autoinhibition: A New Strategy to Target the Cytoskeletal Remodeling Machinery in Cancer Cells

Isolation, Amino Acid Sequence and Biological Activities of Novel Long-Chain Polyamine-Associated Peptide Toxins from the Sponge Axinyssa aculeata

PB2088: ABBV‐383 IN COMBINATION WITH ANTI‐CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION

Full Domain Closure of the Ligand-binding Core of the Ionotropic Glutamate Receptor iGluR5 Induced by the High Affinity Agonist Dysiherbaine and the Functional Antagonist 8,9-Dideoxyneodysiherbaine

Pharmacological activity of C10-substituted analogs of the high-affinity kainate receptor agonist dysiherbaine

Total Synthesis and Biological Evaluation of Neodysiherbaine A and Analogues

Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors

Critical Roles for the M3 S2 Transduction Linker Domain in Kainate Receptor Assembly and Postassembly Trafficking

Cover Picture: Isolation, Amino Acid Sequence and Biological Activities of Novel Long-Chain Polyamine-Associated Peptide Toxins from the Sponge Axinyssa aculeata (ChemBioChem 14/2011)

Abstract 2130: Small molecule activation of diaphanous-related formins as a novel anti-cancer strategy

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Abstract 2539: Reactivating tumor suppression with small-molecule deregulators of the Rho-regulated diaphanous-related formin autoinhibitory mechanism

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Mechanisms of membrane estrogen receptor-α-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies

Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Cross-Study Multivariable Analysis of the Impact of Adding Rituximab to Venetoclax on the Depth and Durability of Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Suchergebnisse filtern